Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine - PubMed (original) (raw)
Clinical Trial
. 2001 Sep 1;61(17):6451-8.
A K Palucka, M Dhodapkar, S Burkeholder, N Taquet, A Rolland, S Taquet, S Coquery, K M Wittkowski, N Bhardwaj, L Pineiro, R Steinman, J Fay
Affiliations
- PMID: 11522640
Clinical Trial
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
J Banchereau et al. Cancer Res. 2001.
Abstract
Immunization to multiple defined tumor antigens for specific immune therapy of human cancer has thus far proven difficult. Eighteen HLA A*0201(+) patients with metastatic melanoma received injections s.c. of CD34(+)progenitor-derived autologous dendritic cells (DCs), which included Langerhans cells. DCs were pulsed with peptides derived from four melanoma antigens [(MelAgs) MelanA/MART-1, tyrosinase, MAGE-3, and gp100], as well as influenza matrix peptide (Flu-MP) and keyhole limpet hemocyanin (KLH) as control antigens. Overall immunological effects were assessed by comparing response profiles using marginal likelihood scores. DC injections were well tolerated except for progressive vitiligo in two patients. DCs induced an immune response to control antigens (KLH, Flu-MP) in 16 of 18 patients. An enhanced immune response to one or more MelAgs was seen in these same 16 patients, including 10 patients who responded to >2 MelAgs. The two patients failing to respond to both control and tumor antigens experienced rapid tumor progression. Of 17 patients with evaluable disease, 6 of 7 patients with immunity to two or less MelAgs had progressive disease 10 weeks after study entry, in contrast to tumor progression in only 1 of 10 patients with immunity to >2 MelAgs. Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015).
Similar articles
- Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, Fay J, Banchereau J. Palucka AK, et al. J Immunother. 2003 Sep-Oct;26(5):432-9. doi: 10.1097/00002371-200309000-00006. J Immunother. 2003. PMID: 12973032 Clinical Trial. - Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Lesterhuis WJ, et al. Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19. Clin Cancer Res. 2011. PMID: 21771874 - Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J. Palucka AK, et al. J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b. J Immunother. 2006. PMID: 16971810 Clinical Trial. - Dendritic cells: controllers of the immune system and a new promise for immunotherapy.
Banchereau J, Fay J, Pascual V, Palucka AK. Banchereau J, et al. Novartis Found Symp. 2003;252:226-35; discussion 235-8, 257-67. Novartis Found Symp. 2003. PMID: 14609222 Review. - Novel dendritic cell-based vaccination in late stage melanoma.
Schneble EJ, Yu X, Wagner TE, Peoples GE. Schneble EJ, et al. Hum Vaccin Immunother. 2014;10(11):3132-8. doi: 10.4161/hv.29110. Hum Vaccin Immunother. 2014. PMID: 25483650 Free PMC article. Review.
Cited by
- Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I. Jouanneau E, et al. Cancer Immunol Immunother. 2006 Mar;55(3):254-67. doi: 10.1007/s00262-005-0040-7. Epub 2005 Aug 27. Cancer Immunol Immunother. 2006. PMID: 16133115 Free PMC article. - Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S. Ardon H, et al. J Neurooncol. 2010 Sep;99(2):261-72. doi: 10.1007/s11060-010-0131-y. Epub 2010 Feb 10. J Neurooncol. 2010. PMID: 20146084 - Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G. Schuler-Thurner B, et al. J Exp Med. 2002 May 20;195(10):1279-88. doi: 10.1084/jem.20012100. J Exp Med. 2002. PMID: 12021308 Free PMC article. Clinical Trial. - Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.
Makino K, Long MD, Kajihara R, Matsueda S, Oba T, Kanehira K, Liu S, Ito F. Makino K, et al. J Immunother Cancer. 2022 Jan;10(1):e003827. doi: 10.1136/jitc-2021-003827. J Immunother Cancer. 2022. PMID: 35101945 Free PMC article. - FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy.
Fiammenghi L, Ancarani V, Rosales T, Knutson JR, Petrini M, Granato AM, Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P. Fiammenghi L, et al. J Transl Med. 2010 Jun 3;8:52. doi: 10.1186/1479-5876-8-52. J Transl Med. 2010. PMID: 20525246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials